🇺🇸 FDA
Patent

US 10035844

Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein

granted A61KA61K2039/505A61K39/42

Quick answer

US patent 10035844 (Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
32
CPC classes
A61K, A61K2039/505, A61K39/42, A61K45/06, A61P